CNTB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	12 407.00
Średni wolumen	162 490
Kapitalizacja rynkowa	78.80M
EPS	$0 ( 2024-04-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.320
ATR14	$0.0150 (1.04%)

Connect Biopharma Korelacja

10 Najbardziej pozytywne korelacje
PWFL	0.908
REPL	0.884
NWLI	0.883
GGAL	0.881
NYMTP	0.878
JOUT	0.874
ANPC	0.873
OM	0.872
SIOX	0.872
AMYT	0.871

10 Najbardziej negatywne korelacje
LARK	-0.9
HMNF	-0.888
RMRM	-0.882
PCRX	-0.879
THTX	-0.868
USCB	-0.866
MARK	-0.865
SNPX	-0.864
SSB	-0.859
GOSS	-0.858

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Connect Biopharma Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-14.50

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-14.50

Financial Reports:

No articles found.

Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.